Trial Profile
A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study of ANG-3777 (Formerly BB3) to Improve Graft Function and Reduce the Severity of Kidney Dysfunction or Delayed Graft Function Following Kidney Transplantation in Recipients of a Deceased Donor Kidney
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Jun 2023
Price :
$35
*
At a glance
- Drugs Terevalefim (Primary)
- Indications Delayed graft function
- Focus Registrational; Therapeutic Use
- Acronyms GIFT
- Sponsors Angion Biomedica; Elicio Therapeutics
- 01 Jun 2023 According to an Elicio Therapeutics media release, Angion Biomedica merged with the Elicio Therapeutics and the combined company is called as Elicio Therapeutics.
- 02 Aug 2022 According to a CSL Vifor media release, Vifor Pharma has been acquired by CSL and renamed to CSL Vifor.
- 27 Oct 2021 Primary endpoint of severity of DGF has not been met, according to a Vifor Pharma media release.